| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $400,000 ) |
| | 2025 | 2025 | LIFENGINE ANIMAL HEALTH LABORATORIES INCORPORATED | 3388 MIKE COLLINS DR STE 1 | EAGAN | MN | 55121-2410 | DAKOTA | USA | R43CA295178 | c-MYB overexpression for exhaustion resistant CAR-T cell therapies | 000 | 1 | NIH | 8/4/2025 | $400,000 |
|
| Issue Date FY: 2024 ( Subtotal = $0 ) |
| | 2024 | 2022 | LIFENGINE ANIMAL HEALTH LABORATORIES INCORPORATED | 3388 MIKE COLLINS DR STE 1 | EAGAN | MN | 55121-2410 | DAKOTA | USA | R43TR003743 | A non-viral gene editing platform for cell therapies and translational autoimmune disease modeling | 000 | 1 | NIH | 3/14/2024 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $337,433 ) |
| | 2022 | 2022 | LIFENGINE ANIMAL HEALTH LABORATORIES INCORPORATED | 221 1ST AVE SW STE 202-22 | ROCHESTER | MN | 55902-4504 | OLMSTED | USA | R43TR003743 | A non-viral gene editing platform for cell therapies and translational autoimmune disease modeling | 000 | 1 | NIH | 2/22/2022 | $337,433 |
|
|
